Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 161Neoplasm Metastasis 22Neoplasms 20Advanced Breast Cancer 13Ovarian Neoplasms 11Carcinoma, Non-Small-Cell Lung 10Hereditary Sensory and Autonomic Neuropathies 9Endometrial Neoplasms 8Triple Negative Breast Neoplasms 7Colorectal Neoplasms 6Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms 5Recurrence 4Neoplasms by Site 4Multiple Endocrine Neoplasia Type 1 4Breast Diseases 4Small Cell Lung Carcinoma 3Head and Neck Neoplasms 3Carcinoma, Ovarian Epithelial 3Uterine Neoplasms 2Stomach Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma 2Locally Advanced (Inoperable) or Metastatic Breast Cancer 2Liposarcoma 2HER2-positive Metastatic Breast Cancer 2Advanced Solid Tumors 2Advanced Solid Tumor 2Urologic Neoplasms 1

Interventions

Paclitaxel 47Carboplatin 38liposomal doxorubicin 25Bevacizumab 23Gemcitabine 18Topotecan 15pembrolizumab 14mirvetuximab soravtansine 11rucaparib 8niraparib 7Cisplatin 71-dodecylpyridoxal 7trebananib 6Drug Therapy 6130-nm albumin-bound paclitaxel 6Nivolumab 5Cyclophosphamide 5cemiplimab 4sarilumab 3relacorilant 3pazopanib 3oregovomab 3olaparib 3Doxorubicin 3Docetaxel 3Albumin-Bound Paclitaxel 3tocilizumab 2seribantumab 2phenoxodiol 2pegfilgrastim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Fallopian Tube Neoplasms × Fulvestrant × Clear all
NCT05867251 2025-11-19

Study of AVZO-021 in Patients With Advanced Solid Tumors

Avenzo Therapeutics, Inc.

Phase 1/2 Recruiting
430 enrolled
BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡